Augustinus investment concluded successfully
The investment in Abacus Medicine by Chr. Augustinus Fabrikker has today been concluded successfully.
Following the expected approval by the competition authorities in Denmark (Konkurrence- og Forbrugerstyrelsen) and in Germany (Bundeskartellamt) the remaining paperwork was completed on Monday, September 16th.
Chr. Augustinus Fabrikker invests EUR 48 million to acquire an ownership stake of just over one third of the shares in Abacus Medicine. Flemming Wagner continues as the company’s CEO and majority shareholder.